IL-20Rα Activators
IL-20Rα activators belong to a distinctive class of chemical compounds that interact with the interleukin-20 receptor alpha (IL-20Rα) signaling pathway. The IL-20Rα receptor is a member of the interleukin-20 receptor family, which is part of the broader interleukin-10 cytokine family. This receptor is predominantly expressed in various tissues, including skin, lung, and gastrointestinal tract, underscoring its involvement in immune responses and tissue homeostasis. IL-20Rα activators modulate the activity of this receptor, influencing downstream signaling cascades and cellular responses.
At the molecular level, IL-20Rα activators exert their effects by binding to the IL-20Rα subunit, a key component of the receptor complex. This interaction can lead to the activation of intracellular pathways, such as the JAK-STAT pathway, which plays a pivotal role in regulating immune and inflammatory responses. By influencing these pathways, IL-20Rα activators can potentially modulate cellular processes associated with inflammation, tissue repair, and immune regulation. The intricate interplay between IL-20Rα activators and the interleukin-20 receptor family provides a fascinating avenue for understanding the molecular mechanisms that govern immune responses and tissue homeostasis, with implications for various physiological and pathological conditions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 Inhibitor that modulates the JAK-STAT pathway, potentially enhancing IL-20Rα activation. Used in myelofibrosis therapy. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
STAT3 Inhibitor that directly blocks STAT3 activation, a component crucial for IL-20Rα activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB Inhibitor with anti-inflammatory properties, potentially influencing IL-20Rα through modulation of the NF-κB pathway and its role in activation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome Inhibitor used in cancer therapy, potentially impacting IL-20Rα by affecting protein degradation and cellular regulation linked to activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK Inhibitor, which may regulate the inflammatory response associated with IL-20Rα signaling and its activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K Inhibitor impacting the PI3K-Akt pathway, with potential downstream effects on IL-20Rα activation. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
Akt Inhibitor that modulates the Akt signaling pathway, potentially influencing IL-20Rα activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR Inhibitor, part of the PI3K-Akt-mTOR pathway, which could indirectly enhance IL-20Rα activation. Used as an immunosuppressant. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR Inhibitor with implications for the PI3K-Akt-mTOR pathway, potentially influencing IL-20Rα in the context of cancer treatment and activation. | ||||||